Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SHC Stock Forecast 2025-2026
$11.16
Current Price
$3.21B
Market Cap
Buy 4
Hold 4
Sell 0
Wall St Analyst Ratings
Distance to SHC Price Targets
+52.4%
To High Target of $17.00
+25.5%
To Median Target of $14.00
+7.6%
To Low Target of $12.00
SHC Price Momentum
+8.0%
1 Week Change
-5.3%
1 Month Change
-2.2%
1 Year Change
-18.5%
Year-to-Date Change
-34.7%
From 52W High of $17.08
+17.1%
From 52W Low of $9.53
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Sotera Health (SHC) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on SHC and similar high-potential opportunities.
Latest SHC Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, SHC has a neutral consensus with a median price target of $14.00 (ranging from $12.00 to $17.00). The overall analyst rating is Buy (7.8/10). Currently trading at $11.16, the median forecast implies a 25.5% upside. This outlook is supported by 4 Buy, 4 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Luke Sergott at Barclays, projecting a 52.4% upside. Conversely, the most conservative target is provided by Luke Sergott at Barclays, suggesting a 7.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SHC Analyst Ratings
4
Buy
4
Hold
0
Sell
SHC Price Target Range
Low
$12.00
Average
$14.00
High
$17.00
Current: $11.16
Latest SHC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SHC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 23, 2025 | Piper Sandler | Jason Bednar | Neutral | Maintains | $13.00 |
| Apr 10, 2025 | Barclays | Luke Sergott | Overweight | Maintains | $12.00 |
| Feb 28, 2025 | Barclays | Luke Sergott | Overweight | Maintains | $16.00 |
| Feb 18, 2025 | Barclays | Luke Sergott | Overweight | Maintains | $17.00 |
| Nov 21, 2024 | RBC Capital | Sean Dodge | Outperform | Reiterates | $17.00 |
| Nov 6, 2024 | Citigroup | Patrick Donnelly | Buy | Maintains | $20.00 |
| Aug 6, 2024 | RBC Capital | Sean Dodge | Outperform | Reiterates | $17.00 |
| Aug 6, 2024 | Barclays | Luke Sergott | Overweight | Maintains | $17.00 |
| May 21, 2024 | Piper Sandler | Jason Bednar | Neutral | Initiates | $13.00 |
| Apr 10, 2024 | Barclays | Luke Sergott | Overweight | Maintains | $14.00 |
| Apr 3, 2024 | Citigroup | Patrick Donnelly | Buy | Upgrade | $16.00 |
| Mar 25, 2024 | Jefferies | David Windley | Buy | Upgrade | $15.50 |
| Mar 11, 2024 | RBC Capital | Sean Dodge | Outperform | Reiterates | $20.00 |
| Mar 4, 2024 | RBC Capital | Sean Dodge | Outperform | Reiterates | $20.00 |
| Feb 28, 2024 | Barclays | Luke Sergott | Overweight | Maintains | $19.00 |
| Feb 6, 2024 | Keybanc | Brett Fishbin | Sector Weight | Initiates | $0.00 |
| Jan 25, 2024 | Barclays | Luke Sergott | Overweight | Maintains | $17.00 |
| Nov 2, 2023 | Barclays | Luke Sergott | Overweight | Maintains | $15.00 |
| Nov 2, 2023 | RBC Capital | Sean Dodge | Outperform | Maintains | $20.00 |
| Aug 4, 2023 | Keybanc | Matthew Mishan | Overweight | Maintains | $23.00 |
Sotera Health Company (SHC) Competitors
The following stocks are similar to Sotera Health based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Sotera Health Company (SHC) Financial Data
Sotera Health Company has a market capitalization of $3.21B with a P/E ratio of 69.7x. The company generates $1.10B in trailing twelve-month revenue with a 4.0% profit margin.
Revenue growth is -6.5% quarter-over-quarter, while maintaining an operating margin of +34.0% and return on equity of +10.5%.
Valuation Metrics
Market Cap
$3.21B
Enterprise Value
$5.23B
P/E Ratio
69.7x
PEG Ratio
13.8x
Price/Sales
2.9x
Growth & Margins
Revenue Growth (YoY)
-6.5%
Gross Margin
+56.6%
Operating Margin
+34.0%
Net Margin
+4.0%
EPS Growth
-68.1%
Financial Health
Cash/Price Ratio
+8.8%
Current Ratio
2.8x
Debt/Equity
580.5x
ROE
+10.5%
ROA
+6.8%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Sotera Health Company (SHC) Business Model
About Sotera Health Company
What They Do
Provides essential health and sterilization services.
Business Model
The company operates through three main divisions: Sterigenics, Nordion, and Nelson Labs. It generates revenue by offering sterilization solutions, supplying critical materials for radiation sterilization, and providing laboratory testing and consultancy services to ensure compliance with health regulations across various industries.
Additional Information
Sotera Health is vital for public health and safety, serving sectors such as medical devices, pharmaceuticals, and food. The company emphasizes innovation and reliability in its services, positioning itself as a key player in maintaining rigorous safety standards globally.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
3,000
CEO
Mr. Michael B. Petras Jr.
Country
United States
IPO Year
2020
Website
soterahealth.comSotera Health Company (SHC) Latest News & Analysis
Latest News
Quick Summary
Sotera Health Company (Nasdaq: SHC) will release its Q1 2025 financial results on May 1, 2025, before market open, followed by a conference call at 9:00 a.m. EDT.
Why It Matters
Sotera Health's upcoming earnings release and conference call will provide insights into its financial performance and operational updates, influencing market sentiment and stock valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Investors should monitor Sotera Health (SHC) stock due to recent activity in the options market.
Why It Matters
Increased activity in Sotera Health's options market may signal shifts in investor sentiment or expectations for price volatility, impacting stock performance and potential returns.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Sotera Health provides sterilization and lab services with strong customer retention. Despite a 6% FY24 revenue decline, it maintains ~50% EBITDA margins and plans to reduce CapEx and debt.
Why It Matters
Sotera Health's strong customer retention, high margins, and strategic focus on CapEx reduction and debt management signal resilience, even amid revenue challenges. This could enhance long-term investor confidence.
Source: Seeking Alpha
Market Sentiment:
Positive
Nelson Labs Launches Innovative Rapid Sterility Testing to Significantly Expedite Product Sterility Results
1 month ago
Quick Summary
Rapid Sterility Testing offers product sterility results in as little as 6 days, applicable across medical devices and pharmaceuticals, potentially enhancing industry efficiency.
Why It Matters
Rapid Sterility Testing accelerates product approval timelines for medical devices and pharmaceuticals, potentially increasing market competitiveness and revenue for companies in those sectors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Sotera Health Company (NASDAQ:SHC) will hold its Q4 2024 earnings conference call on February 27, 2025, at 9:00 AM ET, featuring key executives and analysts from major firms.
Why It Matters
Sotera Health's earnings call reveals financial performance and future outlook, impacting stock valuations and investor sentiment based on insights from key executives and analysts.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Sotera Health Company (Nasdaq: SHC) reported its Q4 and full-year 2024 financial results and provided its initial outlook for 2025.
Why It Matters
Sotera Health's financial results and outlook can influence stock performance, impacting investor sentiment and decisions in the healthcare sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About SHC Stock
What is Sotera Health Company's (SHC) stock forecast for 2025?
Based on our analysis of 13 Wall Street analysts, Sotera Health Company (SHC) has a median price target of $14.00. The highest price target is $17.00 and the lowest is $12.00.
Is SHC stock a good investment in 2025?
According to current analyst ratings, SHC has 4 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $11.16. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SHC stock?
Wall Street analysts predict SHC stock could reach $14.00 in the next 12 months. This represents a 25.5% increase from the current price of $11.16. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Sotera Health Company's business model?
The company operates through three main divisions: Sterigenics, Nordion, and Nelson Labs. It generates revenue by offering sterilization solutions, supplying critical materials for radiation sterilization, and providing laboratory testing and consultancy services to ensure compliance with health regulations across various industries.
What is the highest forecasted price for SHC Sotera Health Company?
The highest price target for SHC is $17.00 from Luke Sergott at Barclays, which represents a 52.4% increase from the current price of $11.16.
What is the lowest forecasted price for SHC Sotera Health Company?
The lowest price target for SHC is $12.00 from Luke Sergott at Barclays, which represents a 7.6% increase from the current price of $11.16.
What is the overall SHC consensus from analysts for Sotera Health Company?
The overall analyst consensus for SHC is neutral. Out of 13 Wall Street analysts, 4 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $14.00.
How accurate are SHC stock price projections?
Stock price projections, including those for Sotera Health Company, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 8:51 PM UTC